Data sourcesSEC Form 43h ago
House PTR3h ago
SEC 13F3h ago
Robinhood Chain3h ago
Public companyEnliven Therapeutics, Inc.
ELVNCIK 0001672619
Price$49.43
1 year+167.2%
Disclosed transactions54
Buys / sells0 / 34
Max Insider Score26
Connections with evidence6
ELVN · disclosed activity on price
| Score | Actor | Security | Side | Value | Executed | Disclosed | Lag | Source | Evidence |
|---|
| 0 | CLCollins Helen LouiseCHIEF MEDICAL OFFICER | ELVNEnliven Therapeutics, Inc. Option exercise · 10b5-1 plan | M | — 5,000 sh | Oct 19, 2026 |
| Oct 21, 2026 traded Oct 19, 2026 |
| 0 | CLCollins Helen LouiseCHIEF MEDICAL OFFICER | ELVNEnliven Therapeutics, Inc. Option exercise · 10b5-1 plan | M | $12K 5,000 sh | Oct 19, 2026 | Oct 21, 2026 traded Oct 19, 2026 | +2d | SEC Form 4 | |
| 0 | HBHohl BenjaminCHIEF FINANCIAL OFFICER | ELVNEnliven Therapeutics, Inc. Option exercise · 10b5-1 plan | M | — 6,018 sh | Oct 19, 2026 | Oct 21, 2026 traded Oct 19, 2026 | +2d | SEC Form 4 | |
| 10 | HBHohl BenjaminCHIEF FINANCIAL OFFICER | ELVNEnliven Therapeutics, Inc. Open-market sale · 10b5-1 plan | SELL | $232K 6,018 sh | Oct 19, 2026 | Oct 21, 2026 traded Oct 19, 2026 | +2d | SEC Form 4 | |
| 10 | CLCollins Helen LouiseCHIEF MEDICAL OFFICER | ELVNEnliven Therapeutics, Inc. Open-market sale · 10b5-1 plan | SELL | $192K 5,000 sh | Oct 19, 2026 | Oct 21, 2026 traded Oct 19, 2026 | +2d | SEC Form 4 | |
| 0 | HBHohl BenjaminCHIEF FINANCIAL OFFICER | ELVNEnliven Therapeutics, Inc. Option exercise · 10b5-1 plan | M | $89K 6,018 sh | Oct 19, 2026 | Oct 21, 2026 traded Oct 19, 2026 | +2d | SEC Form 4 | |
| 2 | HBHohl BenjaminCHIEF FINANCIAL OFFICER | ELVNEnliven Therapeutics, Inc. Option exercise · 10b5-1 plan | M | $59K 3,982 sh | Sep 17, 2026 | Sep 21, 2026 traded Sep 17, 2026 | +4d | SEC Form 4 | |
| 13 | HBHohl BenjaminCHIEF FINANCIAL OFFICER | ELVNEnliven Therapeutics, Inc. Open-market sale · 10b5-1 plan | SELL | $111K 2,194 sh | Sep 17, 2026 | Sep 21, 2026 traded Sep 17, 2026 | +4d | SEC Form 4 | |
| 0 | HBHohl BenjaminCHIEF FINANCIAL OFFICER | ELVNEnliven Therapeutics, Inc. Option exercise · 10b5-1 plan | M | — 3,982 sh | Sep 17, 2026 | Sep 21, 2026 traded Sep 17, 2026 | +4d | SEC Form 4 | |
| 6 | HBHohl BenjaminCHIEF FINANCIAL OFFICER | ELVNEnliven Therapeutics, Inc. Open-market sale · 10b5-1 plan | SELL | $15K 289 sh | Sep 17, 2026 | Sep 21, 2026 traded Sep 17, 2026 | +4d | SEC Form 4 | |
| 3 | CLCollins Helen LouiseCHIEF MEDICAL OFFICER | ELVNEnliven Therapeutics, Inc. Option exercise · 10b5-1 plan | M | $12K 5,000 sh | Sep 17, 2026 | Sep 21, 2026 traded Sep 17, 2026 | +4d | SEC Form 4 | |
| 0 | CLCollins Helen LouiseCHIEF MEDICAL OFFICER | ELVNEnliven Therapeutics, Inc. Option exercise · 10b5-1 plan | M | — 5,000 sh | Sep 17, 2026 | Sep 21, 2026 traded Sep 17, 2026 | +4d | SEC Form 4 | |
| 6 | CLCollins Helen LouiseCHIEF MEDICAL OFFICER | ELVNEnliven Therapeutics, Inc. Open-market sale · 10b5-1 plan | SELL | $12K 240 sh | Sep 17, 2026 | Sep 21, 2026 traded Sep 17, 2026 | +4d | SEC Form 4 | |
| 13 | CLCollins Helen LouiseCHIEF MEDICAL OFFICER | ELVNEnliven Therapeutics, Inc. Open-market sale · 10b5-1 plan | SELL | $94K 1,844 sh | Sep 17, 2026 | Sep 21, 2026 traded Sep 17, 2026 | +4d | SEC Form 4 | |
| 13 | CLCollins Helen LouiseCHIEF MEDICAL OFFICER | ELVNEnliven Therapeutics, Inc. Open-market sale · 10b5-1 plan | SELL | $146K 2,916 sh | Sep 17, 2026 | Sep 21, 2026 traded Sep 17, 2026 | +4d | SEC Form 4 | |
| 13 | HBHohl BenjaminCHIEF FINANCIAL OFFICER | ELVNEnliven Therapeutics, Inc. Open-market sale · 10b5-1 plan | SELL | $177K 3,535 sh | Sep 17, 2026 | Sep 21, 2026 traded Sep 17, 2026 | +4d | SEC Form 4 | |
| 11 | HBHohl BenjaminCHIEF FINANCIAL OFFICER | ELVNEnliven Therapeutics, Inc. Open-market sale · 10b5-1 plan | SELL | $270K 4,630 sh | Aug 17, 2026 | Aug 19, 2026 traded Aug 17, 2026 | +2d | SEC Form 4 | |
| 4 | HBHohl BenjaminCHIEF FINANCIAL OFFICER | ELVNEnliven Therapeutics, Inc. Open-market sale · 10b5-1 plan | SELL | $82K 1,388 sh | Aug 17, 2026 | Aug 19, 2026 traded Aug 17, 2026 | +2d | SEC Form 4 | |
| 14 | HBHohl BenjaminCHIEF FINANCIAL OFFICER | ELVNEnliven Therapeutics, Inc. Open-market sale · 10b5-1 plan | SELL | $59K 1,379 sh | Jun 17, 2026 | Jun 22, 2026 traded Jun 17, 2026 | +5d | SEC Form 4 | |
| 9 | HBHohl BenjaminCHIEF FINANCIAL OFFICER | ELVNEnliven Therapeutics, Inc. Option exercise · 10b5-1 plan | M | — 6,018 sh | Jun 17, 2026 | Jun 22, 2026 traded Jun 17, 2026 | +5d | SEC Form 4 | |
| 14 | HBHohl BenjaminCHIEF FINANCIAL OFFICER | ELVNEnliven Therapeutics, Inc. Open-market sale · 10b5-1 plan | SELL | $55K 1,238 sh | Jun 17, 2026 | Jun 22, 2026 traded Jun 17, 2026 | +5d | SEC Form 4 | |
| 9 | HBHohl BenjaminCHIEF FINANCIAL OFFICER | ELVNEnliven Therapeutics, Inc. Option exercise · 10b5-1 plan | M | $15K 6,018 sh | Jun 17, 2026 | Jun 22, 2026 traded Jun 17, 2026 | +5d | SEC Form 4 | |
| 18 | HBHohl BenjaminCHIEF FINANCIAL OFFICER | ELVNEnliven Therapeutics, Inc. Open-market sale · 10b5-1 plan | SELL | $149K 3,401 sh | Jun 17, 2026 | Jun 22, 2026 traded Jun 17, 2026 | +5d | SEC Form 4 | |
| 1 | CLCollins Helen LouiseCHIEF MEDICAL OFFICER | ELVNEnliven Therapeutics, Inc. Open-market sale · 10b5-1 plan | SELL | $6,413 140 sh | Apr 17, 2026 | Apr 21, 2026 traded Apr 17, 2026 | +4d | SEC Form 4 | |
| 8 | CLCollins Helen LouiseCHIEF MEDICAL OFFICER | ELVNEnliven Therapeutics, Inc. Open-market sale · 10b5-1 plan | SELL | $115K 2,419 sh | Apr 17, 2026 | Apr 21, 2026 traded Apr 17, 2026 | +4d | SEC Form 4 | |
| 8 | CLCollins Helen LouiseCHIEF MEDICAL OFFICER | ELVNEnliven Therapeutics, Inc. Open-market sale · 10b5-1 plan | SELL | $117K 2,441 sh | Apr 17, 2026 | Apr 21, 2026 traded Apr 17, 2026 | +4d | SEC Form 4 | |
| 0 | CLCollins Helen LouiseCHIEF MEDICAL OFFICER | ELVNEnliven Therapeutics, Inc. Option exercise · 10b5-1 plan | M | — 5,000 sh | Apr 17, 2026 | Apr 21, 2026 traded Apr 17, 2026 | +4d | SEC Form 4 | |
| 3 | CLCollins Helen LouiseCHIEF MEDICAL OFFICER | ELVNEnliven Therapeutics, Inc. Option exercise · 10b5-1 plan | M | $12K 5,000 sh | Apr 17, 2026 | Apr 21, 2026 traded Apr 17, 2026 | +4d | SEC Form 4 | |
| 14 | CLCollins Helen LouiseCHIEF MEDICAL OFFICER | ELVNEnliven Therapeutics, Inc. Option exercise · 10b5-1 plan | M | $99K 40.0K sh | Mar 25, 2026 | Mar 27, 2026 traded Mar 25, 2026 | +2d | SEC Form 4 | |
| 26 | CLCollins Helen LouiseCHIEF MEDICAL OFFICER | ELVNEnliven Therapeutics, Inc. Open-market sale · 10b5-1 plan | SELL | $1.40M 40.0K sh | Mar 25, 2026 | Mar 27, 2026 traded Mar 25, 2026 | +2d | SEC Form 4 | |
| 7 | CLCollins Helen LouiseCHIEF MEDICAL OFFICER | ELVNEnliven Therapeutics, Inc. Option exercise · 10b5-1 plan | M | — 40.0K sh | Mar 25, 2026 | Mar 27, 2026 traded Mar 25, 2026 | +2d | SEC Form 4 | |
| 8 | PAPatel AnishCHIEF OPERATING OFFICER | ELVNEnliven Therapeutics, Inc. Grant or award | A | — 120.0K sh | Feb 12, 2026 | Feb 17, 2026 traded Feb 12, 2026 | +5d | SEC Form 4 | |
| 8 | LPLyssikatos Joseph PCHIEF SCIENTIFIC OFFICER | ELVNEnliven Therapeutics, Inc. Grant or award | A | — 112.5K sh | Feb 12, 2026 | Feb 17, 2026 traded Feb 12, 2026 | +5d | SEC Form 4 | |
| 8 | PAPatel AnishCHIEF OPERATING OFFICER | ELVNEnliven Therapeutics, Inc. Grant or award | A | — 20.0K sh | Feb 12, 2026 | Feb 17, 2026 traded Feb 12, 2026 | +5d | SEC Form 4 | |
| 8 | LPLyssikatos Joseph PCHIEF SCIENTIFIC OFFICER | ELVNEnliven Therapeutics, Inc. Grant or award | A | — 18.8K sh | Feb 12, 2026 | Feb 17, 2026 traded Feb 12, 2026 | +5d | SEC Form 4 | |
| 1 | LPLyssikatos Joseph PCHIEF SCIENTIFIC OFFICER | ELVNEnliven Therapeutics, Inc. Open-market sale · 10b5-1 plan | SELL | $145K 5,000 sh | Feb 6, 2026 | Feb 10, 2026 traded Feb 6, 2026 | +4d | SEC Form 4 | |
| 6 | LPLyssikatos Joseph PCHIEF SCIENTIFIC OFFICER | ELVNEnliven Therapeutics, Inc. Open-market sale · 10b5-1 plan | SELL | $145K 5,491 sh | Jan 20, 2026 | Jan 22, 2026 traded Jan 20, 2026 | +2d | SEC Form 4 | |
| 9 | LPLyssikatos Joseph PCHIEF SCIENTIFIC OFFICER | ELVNEnliven Therapeutics, Inc. Open-market sale · 10b5-1 plan | SELL | $390K 14.5K sh | Jan 20, 2026 | Jan 22, 2026 traded Jan 20, 2026 | +2d | SEC Form 4 | |
| 19 | PAPatel AnishCHIEF OPERATING OFFICER | ELVNEnliven Therapeutics, Inc. Open-market sale · 10b5-1 plan | SELL | $1.34M 48.1K sh | Jan 9, 2026 | Jan 13, 2026 traded Jan 9, 2026 | +4d | SEC Form 4 | |
| 6 | PAPatel AnishCHIEF OPERATING OFFICER | ELVNEnliven Therapeutics, Inc. Open-market sale · 10b5-1 plan | SELL | $6,926 243 sh | Jan 9, 2026 | Jan 13, 2026 traded Jan 9, 2026 | +4d | SEC Form 4 | |
| 12 | LPLyssikatos Joseph PCHIEF SCIENTIFIC OFFICER | ELVNEnliven Therapeutics, Inc. Open-market sale · 10b5-1 plan | SELL | $842K 33.8K sh | Jan 8, 2026 | Jan 12, 2026 traded Jan 8, 2026 | +4d | SEC Form 4 | |
| 9 | LPLyssikatos Joseph PCHIEF SCIENTIFIC OFFICER | ELVNEnliven Therapeutics, Inc. Open-market sale · 10b5-1 plan | SELL | $151K 7,500 sh | Jan 8, 2026 | Jan 12, 2026 traded Jan 8, 2026 | +4d | SEC Form 4 | |
| 19 | LPLyssikatos Joseph PCHIEF SCIENTIFIC OFFICER | ELVNEnliven Therapeutics, Inc. Open-market sale · 10b5-1 plan | SELL | $1.46M 50.0K sh | Jan 9, 2026 | Jan 12, 2026 traded Jan 9, 2026 | +3d | SEC Form 4 | |
| 15 | LPLyssikatos Joseph PCHIEF SCIENTIFIC OFFICER | ELVNEnliven Therapeutics, Inc. Open-market sale · 10b5-1 plan | SELL | $1.03M 41.2K sh | Jan 9, 2026 | Jan 12, 2026 traded Jan 9, 2026 | +3d | SEC Form 4 | |
| 13 | HBHohl BenjaminCHIEF FINANCIAL OFFICER | ELVNEnliven Therapeutics, Inc. Option exercise | M | — 13.0K sh | Dec 22, 2025 | Dec 23, 2025 traded Dec 22, 2025 | +1d | SEC Form 4 | |
| 21 | HBHohl BenjaminCHIEF FINANCIAL OFFICER | ELVNEnliven Therapeutics, Inc. Option exercise | M | $32K 13.0K sh | Dec 22, 2025 | Dec 23, 2025 traded Dec 22, 2025 | +1d | SEC Form 4 | |
| 9 | LPLyssikatos Joseph PCHIEF SCIENTIFIC OFFICER | ELVNEnliven Therapeutics, Inc. Open-market sale · 10b5-1 plan | SELL | $84K 5,000 sh | Dec 19, 2025 | Dec 23, 2025 traded Dec 19, 2025 | +4d | SEC Form 4 | |
| 6 | PAPatel AnishCHIEF OPERATING OFFICER | ELVNEnliven Therapeutics, Inc. Open-market sale · 10b5-1 plan | SELL | $37K 1,705 sh | Dec 8, 2025 | Dec 10, 2025 traded Dec 8, 2025 | +2d | SEC Form 4 | |
| 9 | PAPatel AnishCHIEF OPERATING OFFICER | ELVNEnliven Therapeutics, Inc. Open-market sale · 10b5-1 plan | SELL | $103K 4,958 sh | Dec 8, 2025 | Dec 10, 2025 traded Dec 8, 2025 | +2d | SEC Form 4 | |
| 15 | LPLyssikatos Joseph PCHIEF SCIENTIFIC OFFICER | ELVNEnliven Therapeutics, Inc. Open-market sale · 10b5-1 plan | SELL | $11K 492 sh | Nov 19, 2025 | Nov 21, 2025 traded Nov 19, 2025 | +2d | SEC Form 4 | |
| 21 | LPLyssikatos Joseph PCHIEF SCIENTIFIC OFFICER | ELVNEnliven Therapeutics, Inc. Open-market sale · 10b5-1 plan | SELL | $268K 12.0K sh | Nov 19, 2025 | Nov 21, 2025 traded Nov 19, 2025 | +2d | SEC Form 4 | |
| 21 | KSKintz SamuelDirector, PRESIDENT AND CEO | ELVNEnliven Therapeutics, Inc. Open-market sale · 10b5-1 plan | SELL | $273K 12.5K sh | Nov 17, 2025 | Nov 19, 2025 traded Nov 17, 2025 | +2d | SEC Form 4 | |
| 24 | PAPatel AnishCHIEF OPERATING OFFICER | ELVNEnliven Therapeutics, Inc. Open-market sale · 10b5-1 plan | SELL | $105K 6,054 sh | Nov 7, 2025 | Nov 12, 2025 traded Nov 7, 2025 | +5d | SEC Form 4 | |
| 21 | PAPatel AnishCHIEF OPERATING OFFICER | ELVNEnliven Therapeutics, Inc. Open-market sale · 10b5-1 plan | SELL | $11K 613 sh | Nov 7, 2025 | Nov 12, 2025 traded Nov 7, 2025 | +5d | SEC Form 4 | |
Director, PRESIDENT AND CEO · Nov 19, 2025